Expertise in
16
conditions

Birgit Geoerger

Gustave Roussy
Villejuif, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
16
conditions
Gustave Roussy
Villejuif, FR 

Overview

Birgit Geoerger practices practicing medicine in Villejuif, France.

Ms. Geoerger is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Rhabdomyosarcoma, Embryonal Tumor with Multilayered Rosettes, Adult Soft Tissue Sarcoma, and Gliomatosis Cerebri.

She is actively involved in clinical research, co-authoring 162 peer reviewed articles and participating in 7 clinical trials.

Gender

Female

Locations

Gustave Roussy
Villejuif, 94805, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Enrollment Status: Recruiting
Publish Date: July 10, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase I Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors
Phase I Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: June 08, 2026
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
Enrollment Status: Completed
Publish Date: March 02, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Irinotecan, Temozolomide
Study Phase: Phase 1/Phase 2
A Phase 1, Multicentre, Open-Label, Dose-Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Patients With Recurrent or Refractory Solid Tumours
A Phase 1, Multicentre, Open-Label, Dose-Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Patients With Recurrent or Refractory Solid Tumours
Enrollment Status: Terminated
Publish Date: January 21, 2026
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Enrollment Status: Completed
Publish Date: October 03, 2024
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 1
Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
Enrollment Status: Completed
Publish Date: November 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

162 Total Publications

Erdafitinib in Patients With Advanced Solid Tumors With FGFR Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts.
Erdafitinib in Patients With Advanced Solid Tumors With FGFR Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts.
Journal: JCO precision oncology
Published: July 15, 2026

Frequently Asked Questions about Birgit Geoerger

Is Birgit Geoerger a top-rated expert for Rhabdomyosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Birgit Geoerger is classified as an Elite expert for Rhabdomyosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Birgit Geoerger participate in research or clinical trials?

Yes. Birgit Geoerger has published 162 articles and abstracts on conditions like Rhabdomyosarcoma. You can view a list of Birgit Geoerger's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Geoerger's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 8 Advanced Conditions
View All 30 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile